

## **Prematurely ended - Statement**

<b>EudraCT Number:</b>	2011-001474-25
<b>Full title of the study:</b>	A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy (SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma.
<b>Sponsor-Code:</b>	SVM9122
<b>Sponsor:</b>	Charité – Universitätsmedizin Berlin
<b>Principal Investigator/ Study Contact::</b>	Dr. med. Felix Kiecker KLINIK FÜR DERMATOLOGIE, VENEROLOGIE UND ALLERGOLOGIE, Hauttumorzentrum, Charitéplatz 1, 10117 Berlin
<b>Product:</b>	Proleukin (Novartis)
<b>Date of early termination:</b>	2019/12/31
<b>Statement:</b>	Due to difficulties in recruitment and change of employer of the principal investigator in January 2020, no patient was enrolled in the study.